LEPR and cancer: In addition, this association was more pronounced in advanced-stage cancers (stage III/IV) (LEPR rs7602 HR, 0.39, 95% CI, 0.24–0.63; LEPR rs1171278, HR, 0.40, 95% CI, 0.24–0.68) than in those detected at an early stage (stage I/II) (LEPR rs7602, HR, 0.82, 95% CI, 0.51–1.31; LEPR rs1171278, HR, 0.83, 95% CI, 0.49–1.40) (Supplementary Tables S3 and S4).